Table 1.
Baseline characteristics of study cohort.
| Baseline characteristics | |
|---|---|
| Demographics | |
| Patients (n) | 37 |
| Gender (male) | 24 (64.9) |
| Age (years) | 65.7 (41–86) |
| VHL disease | 2 (5.4) |
| Tumor characteristics | |
| Tumors (n) | 1.03 (1–2) |
| Tumor diameter (cm) | 2.2±0.75 |
| TTV (cm3) | 5.4±9.3 |
| ETV (cm3) | 5.3±8.2 |
| Histology (n=21) | |
| Clear cell | 15 (71.4) |
| Papillary | 4 (19.1) |
| Chromophobe | 2 (9.5) |
| TNM stage | |
| 1 | 25 (67.6) |
| 3 | 7 (18.9) |
| 4 | 5 (13.5) |
| RENAL score | 6.5 (4–10) |
| Fuhrman grade | 1.9 (1–3) |
| Treatment characteristics | |
| Ablation | |
| Percutaneous cryoablation | 25 (67.6) |
| Laparoscopic cryoablation | 4 (10.8) |
| Radiofrequency ablation | 8 (21.6) |
| Pre-ablative embolization | 2 (5.4) |
| Previous treatments | |
| Contralateral radical nephrectomy | 4 (10.8) |
| Contralateral partial nephrectomy | 2 (5.4) |
| Ipsilateral partial nephrectomy | 5 (13.5) |
| Imaging modality | |
| Contrast-enhanced MRI | 19 (51.4) |
| Contrast-enhanced CT | 18 (48.6) |
Values are given as n (%), mean (range), or median±SD.
CT, computed tomography; ETV, enhancing tumor volume; MRI, magnetic resonance imaging; TTV, total tumor volume.